ERBB2 and breast cancer: Among the remaining patients, patients with Luminal A breast cancer accounted for the highest proportion (30.7%), followed by patients with triple-negative breast cancer (21.9%), overexpressed Her-2 (18.7%) and Luminal B2 breast cancer (8.0%), and Luminal B1 breast cancer (1.5%) successively.